Pear Therapeutics, Inc.: Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst at ISPOR Europe

Somryst is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia Analysis demonstrated potential per-patient cost reductions over 24 months of

Related Keywords

Vienna ,Wien ,Austria ,United States ,American ,Meara Murphy ,Yuri Maricich ,Pabout Somryst ,Health Care Provider ,Emergency Department ,Software Precertification Pilot Program ,Nasdaq ,American College Of Physicians ,American Academy Of Sleep Medicine ,Pear Therapeutics Us Inc ,Corporate Communications ,Pear Therapeutics Inc ,Chief Medical Officer ,American Academy ,Sleep Medicine ,American College ,Important Safety ,Cognitive Behavioral Therapy ,Health Care ,Clinician Brief Summary Instructions ,Pear Therapeutics ,Precertification Pilot ,Healthcare Resource Utilization ,Chronic Insomnia ,After Treatment ,Pear ,Herapeutics ,Presents ,Meal ,World ,Data ,Showing ,Reduction ,Healthcare ,Resource ,Utilization ,Ssociated ,Costs ,Adults ,Sing ,Omryst ,Spor ,Europe ,